Reimagining Cancer Treatment

Syndax

Determined to realize a future in which people with cancer live longer and better than ever before

Q1 2016 Conference Call

Forward-Looking Statements Disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of the operations of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, and Syndax's expectations for future operations, are forward-looking statements.

Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Company Strategy

Entinostat Breast Cancer

Entinostat Immuno-oncology

New molecules

Financing & Staffing

E2112, a Phase 3 registration trial in advanced HR+ breast cancer patients is underway

E2112 Pivotal Trial Design



Accrual goal = 600 pts
Treatment Cycle = 28d
(1) Treatment is blinded

ENCORE Clinical Trial Program

- The ENCORE trials are designed to establish entinostat's ability to enhance checkpoint efficacy
- Entinostat-checkpoint inhibitor combination trials are expected to generate multiple milestones over the next 18 months

Trial	Partner	Indication	Timeline of Data		
			1H16	2H16	1H17
ENCORE 601	MERCK	NSCLC	ASCO '16 Phase 1b safety: Dose escalation	Phase 1b RP2D	Phase 2
		Melanoma			Phase 2
ENCORE 602	Genentech A Member of the Roche Group	TNBC		Phase 1b safety	
ENCORE 603	MERCK Pfizer	Ovarian			Phase 1b safety

ENCORE 601: Phase 1b Designed in Two Parts

KEYTRUDA® + Entinostat



Study Milestones:

- Completed accrual for dose escalation stage
- Positive safety assessment made by DSMB
- Initiated dose confirmation stage
- Dose confirmation stage estimated completion in Q3-16

1Q Financial Position & Operating Results

Condensed Consolidate Balance Sheet Data as of 3/31/2016

- Cash, cash equivalents, and short-term investments of $133.7M
- Total common shares outstanding 17,782,150
- Common stock, stock options and warrants 20,857,529

Condensed Consolidated Statements of Operations Data for the Three Months Ended March 31, 2016

- Operating loss of $8.8M
- Net loss attributable to common stockholders of $12.9M
- Net loss per share attributable to common (basic and diluted) of $2.85 per share
- Non-cash items included in net loss attributable to common of $6.6M

Summary Highlights

Entinostat

- Phase 3 registration trial ongoing in advanced HR+ breast cancer
  - Granted Breakthrough designation
- Developing as cancer immunotherapy in multiple indications
- Collaborations in place with 3 leading immunotherapy companies
  - Merck & Co., Inc.
  - Genentech, Inc.
  - Merck KGaA, Darmstadt, Germany, and Pfizer Inc.

Experienced leadership team

Current development efforts are fully funded across multiple indications and through significant clinical milestones

Thank you. Questions?